Legend Biotech Debt to Equity Ratio 2019-2022 | LEGN

Current and historical debt to equity ratio values for Legend Biotech (LEGN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Legend Biotech debt/equity for the three months ending March 31, 2022 was 0.29.
Legend Biotech Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.60B $0.44B 1.37
2021-12-31 $0.65B $0.47B 1.37
2021-09-30 $0.59B $0.23B 2.60
2021-06-30 $0.54B $0.34B 1.58
2021-03-31 $0.41B $0.21B 1.98
2020-12-31 $0.44B $0.28B 1.57
2020-09-30 $0.37B $0.34B 1.12
2020-06-30 $0.37B $0.40B 0.93
2020-03-31 $0.53B $-0.17B -3.19
2019-12-31 $0.41B $-0.12B -3.34
2019-09-30 $0.00B $0.00B 0.00
2019-06-30 $0.00B $0.00B 0.00
2019-03-31 $0.00B $0.00B 0.00
2018-12-31 $0.42B $0.01B 48.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.483B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00